Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 million worth of stock in the aftermath of the selloff.
Trending
- 9 No-Capital-Gains-Tax States in 2026 Ranked by Cost of Living
- BKL buys London practice RBS Chartered Accountants
- The Average Millennial 401(k) Balance is Not ‘Superbad’
- Drizzle on top: a new high-end dog food brand is coming for the 1%
- Nasdaq Notches Another New All-Time High: Stock Market Today
- I found an app that finally broke my toxic affair with doomscrolling
- Here’s how long-term investors can benefit from a stock market crash
- Bed Bath & Beyond is seeing new life, as rare sales growth lifts stock more than 30%
